open Menu
Search icon

HER2Low

Publications

2023

Bracht, T., R. Spiller, M. Bauer, S. Kaufhold, V. Hanf, C. Uleer, T. Lantzsch, S. Peschel, J. John, M. Pöhler, E. Weigert, K.-F. Bürrig, J. Buchmann, E. Kantelhardt, C. Thomssen, and M. Vetter (2023). "313P Intrinsic subtypes in a cohort of early breast cancer patients." Annals of Oncology 34: S309. doi.org/10.1016/j.annonc.2023.09.509.

2022

Hiemstra, S., M. Fehling-Kaschek, I. A. Kuijper, L. J. M. Bischoff, L. S. Wijaya, M. Rosenblatt, J. Esselink, A. van Egmond, J. Mos, J. B. Beltman, J. Timmer, B. van de Water, and D. Kaschek (2022). "Dynamic modeling of Nrf2 pathway activation in liver cells after toxicant exposure." Scientific Reports 12(1): 7336. doi.org/10.1038/s41598-022-10857-x.

Kemmer, S., M. Berdiel-Acer, E. Reinz, J. Sonntag, N. Tarade, S. Bernhardt, M. Fehling-Kaschek, M. Hasmann, U. Korf, S. Wiemann, and J. Timmer (2022). "Disentangling ERBB Signaling in Breast Cancer Subtypes - A Model-Based Analysis." Cancers 14(10): 2379. www.mdpi.com/2072-6694/14/10/2379.

Reinhardt, K., K. Stückrath, C. Hartung, S. Kaufhold, C. Uleer, V. Hanf, T. Lantzsch, S. Peschel, J. John, M. Pöhler, M. Bauer, F. K. Bürrig, E. Weigert, J. Buchmann, E. J. Kantelhardt, C. Thomssen, and M. Vetter (2022). "PIK3CA-mutations in breast cancer." Breast Cancer Res Treat 196(3): 483–493. doi.org/10.1007/s10549-022-06637-w.

Schüler, K., D. Bethmann, S. Kaufhold, C. Hartung, K. Stückrath, T. Lantzsch, C. Uleer, V. Hanf, S. Peschel, J. John, M. Pöhler, J. Buchmann, K.-F. Bürrig, E. Weigert, C. Thomssen, E. J. Kantelhardt, and M. Vetter (2022). "Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients." Diagnostics 12(10): 2527. doi.org/10.3390/diagnostics12102527.

2021

Giacomelli, C., J. Jung, A. Wachter, S. Ibing, R. Will, S. Uhlmann, H. Mannsperger, Ö. Sahin, Y. Yarden, T. Beißbarth, U. Korf, C. Körner and S. Wiemann (2021). "Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits." BMC Cancer 21(1): 1–19. HER2Low doi.org/10.1186/s12885-021-08955-6.

Hartung, C., M. Porsch, K. Stückrath, S. Kaufhold, M. S. Staege, V. Hanf, T. Lantzsch, C. Uleer, S. Peschel, J. John, M. Pöhler, E. Weigert, J. Buchmann, K.-F. Bürrig, K. Schüler, D. Bethmann, I. Große, E. J. Kantelhardt, C. Thomssen and M. Vetter (2021). "Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping." BRC: 1–11. HER2low doi.org/10.1159/000519255.

Maia, A. and S. Wiemann (2021). "Cancer-Associated Fibroblasts: Implications for Cancer Therapy." Cancers (Basel) 13(14). HER2Low www.ncbi.nlm.nih.gov/pubmed/34298736.

 

2020

Mitra, D., S. Vega-Rubin-de-Celis, N. Royla, S. Bernhardt, H. Wilhelm, N. Tarade, G. Poschet, M. Buettner, I. Binenbaum, S. Borgoni, M. Vetter, E. J. Kantelhardt, C. Thomssen, A. Chatziioannou, R. Hell, S. Kempa, K. Müller-Decker, and S. Wiemann (2020). "Abrogating GPT2 in triple negative breast cancer inhibits tumor growth and promotes autophagy." Int J Cancer n/a(n/a). doi.org/10.1002/ijc.33456.

Wahjudi, L. W., S. Bernhardt, K. Abnaof, P. Horak, S. Kreutzfeldt, C. Heining, S. Borgoni, C. Becki, D. Berg, D. Richter, B. Hutter, S. Uhrig, K. Pfütze, J. Leichsenring, H. Glimm, B. Brors, C. von Kalle, A. Stenzinger, U. Korf, S. Fröhling, and S. Wiemann (2020). "Integrating proteomics into precision oncology." Int J Cancer n/a(n/a). doi.org/10.1002/ijc.33301.

2019

Bernhardt, S., Tönsing, C., Mitra, D., Erdem, N., Müller-Decker, K., Korf, U., Kreutz, C., Timmer, J. and Wiemann, S. (2019). "Functional proteomics of breast cancer metabolism identifies GLUL as responder during hypoxic adaptation." Journal of Proteome Research. www.ncbi.nlm.nih.gov/pubmed/30609375.

Fehling-Kaschek, M., Peckys, D. B., Kaschek, D., Timmer, J. and Jonge, N. (2019). "Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line." Sci Rep 9(1): 12709. www.ncbi.nlm.nih.gov/pubmed/31481718.

2018

Breunig, C., Erdem, N., Bott, A., Greiwe, J.F., Reinz, E., Bernhardt, S., Giacomelli, C., Wachter, A., Kanthelhardt, E.J., Beißbarth, T., Vetter, M., Wiemann, S., 2018. TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer. Mol Oncol 12, 1447–1463. doi.org/10.1002/1878-0261.12355

Perera-Bel, J., Hutter, B., Heining, C., Bleckmann, A., Fröhlich, M., Fröhling, S., Glimm, H., Brors, B., Beißbarth, T., 2018. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. Genome Med 10, 18. doi.org/10.1186/s13073-018-0529-2

Wolff, A., Bayerlová, M., Gaedcke, J., Kube, D., Beißbarth, T., 2018. A comparative study of RNA-Seq and microarray data analysis on the two examples of rectal-cancer patients and Burkitt Lymphoma cells. PLoS ONE 13, e0197162. https://doi.org/10.1371/journal.pone.0197162

2017

Bernhardt, S., Bayerlová, M., Vetter, M., Wachter, A., Mitra, D., Hanf, V., Lantzsch, T., Uleer, C., Peschel, S., John, J., Buchmann, J., Weigert, E., Bürrig, K.-F., Thomssen, C., Korf, U., Beissbarth, T., Wiemann, S., Kantelhardt, E.J., 2017. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Breast Cancer Res. 19, 112. doi.org/10.1186/s13058-017-0905-7

Bott, A., Erdem, N., Lerrer, S., Hotz-Wagenblatt, A., Breunig, C., Abnaof, K., Wörner, A., Wilhelm, H., Münstermann, E., Ben-Baruch, A., Wiemann, S., 2017. miRNA-1246 induces pro-inflammatory responses in mesenchymal stem/stromal cells by regulating PKA and PP2A. Oncotarget 8, 43897–43914. doi.org/10.18632/oncotarget.14915

Golan-Lavi, R., Giacomelli, C., Fuks, G., Zeisel, A., Sonntag, J., Sinha, S., Köstler, W., Wiemann, S., Korf, U., Yarden, Y., Domany, E., 2017. Coordinated Pulses of mRNA and of Protein Translation or Degradation Produce EGF-Induced Protein Bursts. Cell Rep 18, 3129–3142. doi.org/10.1016/j.celrep.2017.03.014

Peckys, D.B., Korf, U., Wiemann, S., de Jonge, N., 2017. Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers. Mol. Biol. Cell. doi.org/10.1091/mbc.E17-06-0381

2016

von der Heyde, S., Sonntag, J., Kramer, F., Bender, C., Korf, U., Beißbarth, T., 2016. Reconstruction of Protein Networks Using Reverse-Phase Protein Array Data. Methods Mol. Biol. 1362, 227–246. doi.org/10.1007/978-1-4939-3106-4_15

2015

 

Bayerlová, M., Klemm, F., Kramer, F., Pukrop, T., Beißbarth, T., Bleckmann, A., 2015. Newly Constructed Network Models of Different WNT Signaling Cascades Applied to Breast Cancer Expression Data. PLoS ONE 10, e0144014. doi.org/10.1371/journal.pone.0144014

von der Heyde, S., Wagner, S., Czerny, A., Nietert, M., Ludewig, F., Salinas-Riester, G., Arlt, D., Beißbarth, T., 2015. mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer. PLoS ONE 10, e0117818. doi.org/10.1371/journal.pone.0117818

Wachter, A., Bernhardt, S., Beissbarth, T., Korf, U., 2015. Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery. Microarrays 4, 520–539. doi.org/10.3390/microarrays4040520